Fig. 1

GO-FURTHER trial design and clinical endpoints. Longitudinal design for the GO-FURTHER phase III clinical trial. Patients were initially randomized to the GOL or PBO arms of the trial (2:1). GOL patients were initiated onto golimumab treatment at week 0. PBO patients were treated with a placebo at week 0 and were treated with golimumab at week 24 (PBO-NE) or week 16 (PBO-EE). Injections and clinical observations occurred as indicated. EE early escape, GOL golimumab, NE non-early escape, PBO placebo, WAG weeks after initial GOL treatment